Trial Profile
An Open Label, Single Centre, Phase II Pilot Study of Neoadjuvant Dabrafenib + Trametinib in Patients With Resectable American Joint Committee on Cancer (AJCC) Stage IIIB-C BRAF V600 Mutation Positive Melanoma (Neo Combi)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jul 2022
Price :
$35
*
At a glance
- Drugs Dabrafenib (Primary) ; Trametinib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms Neo Combi
- 12 Jul 2022 Planned End Date changed from 1 May 2022 to 1 May 2024.
- 07 Jun 2022 Status changed from active, no longer recruiting to completed, according to Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology.
- 07 Jun 2022 Results assessing 5-year outcomes were presented at the 58th Annual Meeting of the American Society of Clinical Oncology.